Routine annual meeting results filing with no immediate trading catalyst. Monitor future equity grant activity under the expanded plan for potential dilution, but no action warranted based on this filing alone.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Jun 2 $3.14entry
- T+1 · 6mo ago 0.00%α +0.72% · $3.14
- T+5 · 5mo ago 0.00%α +2.96% · $3.14
- T+20 · 5mo ago +0.64%α +2.20% · $3.16
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026. Stockholders approved all four proposals, including the re-election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), a non-binding advisory vote on executive compensation, ratification of Ernst & Young as independent auditor, and a Fourth Amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 to a total of 30,150,000 shares. This is a routine post-meeting filing with no material financial impact.
Key Facts
- Annual meeting held May 28, 2026; all four stockholder proposals approved.
- Class I directors J. Martin Carroll and Sheldon L. Koenig re-elected.
- Fourth Amendment to 2022 Stock Option and Incentive Plan approved, increasing authorized shares by 7,000,000 to 30,150,000 total.
- 257,404,876 shares of common stock outstanding as of March 31, 2026 record date.
- Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026.
Financial Impact
No financial figures reported. The 7,000,000 share increase to the equity incentive plan is a routine authorization; no actual issuance or dilution occurred with this filing.
Risk Factors
- Potential future dilution from equity awards under the expanded 2022 Plan, though no grants are disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-039518 |
| Document: espr-20260528.htm | 0001628280-26-039518 |
| Document: 0001628280-26-039518-index-headers.html | 0001628280-26-039518 |
| Document: 0001628280-26-039518-index.html | 0001628280-26-039518 |
| Document: 0001628280-26-039518.txt | 0001628280-26-039518 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers